VIDEO: Alphyn Biologics’ atopic dermatitis candidate shows positive early results
Click Here to Manage Email Alerts
NEW ORLEANS — In this Healio video exclusive from the American Academy of Dermatology Annual Meeting, Neal Koller, founder and CEO of Alphyn Biologics, discusses the clinical-stage company’s drug pipeline.
Alphyn is currently developing AB-101, an atopic dermatitis treatment candidate that targets the disease’s inflammation, itch and bacteria. The nonsteroidal topical product is in phase 2 trials, in which it has so far met all primary endpoints.
“In early phase 2 trials we are well on track to support our goal of having an atopic dermatitis product that treats both the immune component, the bacterial component and showing results that would lead it to be used continuously long term,” Koller said.
The company plans to initiate a phase 2b trial soon, which they hope to qualify as a pivotal phase 3 trial.